Diffusion Pharmaceuticals Announces FDA Clearance of IND Application for TSC
FDA clearance of trans sodium crocetinate allows Diffusion to proceed with their latest Phase II oxygenation trial.
Diffusion Pharmaceuticals, a biopharmaceutical company developing novel oxygenation therapies, announced on Aug. 30, 2021 that they had obtained investigational new drug (IND) clearance from FDA’s Pulmonology, Allergy, and Critical Care division on their lead product candidate, trans sodium crocetinate (TSC).
Diffusion now has four open INDs related to TSC among select FDA divisions. In addition to the new clearance, there are existing ones from the Cardiology and Nephrology, Neurology, and Oncology divisions.
The trial that will be conducted under the new IND will be a Phase II, double-blind, randomized, placebo-controlled study that will evaluate the effects of TSC on the diffusion of carbon monoxide through the lungs (DLCO) in patients with Interstitial Lung Disease (ILD).
The ILD-DLCO trial will be the third of Diffusion’s three oxygenation trials, which were designed to assess the ability of TSC to enhance oxygen uptake, peripheral oxygenation, and consumption. Their results will inform the selection of TSC’s dosing regimen and initial lead indication, which Diffusion expects will be selected by the end of 2021 and initiated in the first half of 2022, according to a company press release.
“The clearance of our new IND within the Pulmonary Division is a great milestone for Diffusion and TSC,” said Chris Galloway, chief medical officer of Diffusion, in the press release. “Not only does it give us the ability to conduct the ILD-DLCO trial in the US, but also expands our potential regulatory opportunities across multiple divisions at the FDA encompassing numerous therapeutic areas.”
Source: Diffusion
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
